Loading...
Back to narrative

MCOV B Expects MRD Assay Validation To Support Balanced Long Term Outlook

Rising European Labor Costs And Regulatory Burdens Will Squeeze Margins

MCOV B logo
MCOV B
AnalystLowTarget
Not Invested
Published 03 Aug 2025

Update shared on 12 Dec 2025

Fair value Increased 5.33%
n/a
n/a
AnalystLowTarget's Fair Value
n/a
Loading
1Y
18.6%
7D
-4.1%

Analysts have raised their price target on Medicover from €219.05 to €230.73, citing slightly stronger expectations for revenue growth and profit margins that more than offset a modestly higher discount rate and a marginally lower assumed future P/E multiple.

What's in the News

  • Additional DART clinical study results from Oslo University Hospital further validate Medicover Genetics' ctDNA-based MRD assay as a strong predictor of disease progression in unresectable stage III NSCLC, supporting its path toward clinical validation and commercialisation (Key Developments)
  • The updated DART data set, now including 640 plasma samples from 84 patients, shows that detectable ctDNA during and after durvalumab treatment following chemoradiotherapy is strongly associated with inferior progression free survival, underscoring the assay's prognostic value (Key Developments)
  • Detection of ctDNA at six months after initiation of durvalumab and three months after its completion is linked to significantly poorer progression free survival, with ctDNA often indicating disease progression a median of 7.4 months before imaging. This highlights its potential for earlier clinical intervention (Key Developments)
  • The DART study, a multicentre prospective phase II trial of 86 unresectable stage III NSCLC patients across several European centres, received one of the Best Poster awards at the ESMO Congress in Berlin. This boosted the visibility of Medicover Genetics' MRD platform in the oncology community (Key Developments)

Valuation Changes

  • Fair Value: Raised slightly from €219.05 to €230.73 per share, reflecting modestly higher long term earnings expectations.
  • Discount Rate: Increased marginally from 4.92% to 5.07%, implying a slightly higher required return and risk perception.
  • Revenue Growth: Revised up modestly from 8.74% to 8.97% annually, indicating somewhat stronger top line expansion assumptions.
  • Net Profit Margin: Lifted from 4.34% to 4.68%, pointing to a small improvement in expected operating profitability.
  • Future P/E: Trimmed slightly from 27.93x to 26.84x, suggesting a more conservative view on Medicover's long term valuation multiple.

Have other thoughts on Medicover?

Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.

Create Narrative

Disclaimer

AnalystLowTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystLowTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystLowTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.